AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.300
+0.240 (22.64%)
Nov 20, 2024, 4:00 PM EST - Market closed
AN2 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 14.75 | 14.76 | 12.75 | 4.67 | 1.27 | 1.73 |
| Research & Development | 50.01 | 54.87 | 29.51 | 16.91 | 6.02 | 29.33 |
| Operating Expenses | 64.76 | 69.64 | 42.26 | 21.57 | 7.28 | 31.07 |
| Operating Income | -64.76 | -69.64 | -42.26 | -21.57 | -7.28 | -31.07 |
| Interest & Investment Income | - | - | - | 0.07 | 0 | - |
| Currency Exchange Gain (Loss) | - | - | - | -0.04 | - | - |
| Other Non Operating Income (Expenses) | 6.31 | 4.9 | 1.31 | - | -6.32 | -2.74 |
| Pretax Income | -60.7 | -64.73 | -40.96 | -21.54 | -13.6 | -33.81 |
| Net Income | -60.7 | -64.73 | -40.96 | -21.54 | -13.6 | -33.81 |
| Preferred Dividends & Other Adjustments | - | - | 1.82 | 6.52 | 0.98 | 0.59 |
| Net Income to Common | -60.7 | -64.73 | -42.78 | -28.06 | -14.58 | -34.4 |
| Shares Outstanding (Basic) | 30 | 24 | 15 | 3 | 3 | 3 |
| Shares Outstanding (Diluted) | 30 | 24 | 15 | 3 | 3 | 3 |
| Shares Change (YoY) | 41.95% | 53.85% | 481.46% | 2.71% | 0.62% | - |
| EPS (Basic) | -2.04 | -2.74 | -2.79 | -10.64 | -5.68 | -13.48 |
| EPS (Diluted) | -2.04 | -2.74 | -2.79 | -10.64 | -5.68 | -13.48 |
| Free Cash Flow | -61.05 | -53.29 | -33.46 | -20.48 | -5.36 | -14.92 |
| Free Cash Flow Per Share | -2.05 | -2.26 | -2.18 | -7.76 | -2.09 | -5.84 |
| EBIT | -64.76 | -69.64 | -42.26 | -21.57 | -7.28 | -31.07 |
Source: S&P Capital IQ. Standard template.
Financial Sources.